Analyst Rating Update on Juno Therapeutics (JUNO)

Juno Therapeutics (NASDAQ:JUNO) : The consensus on Juno Therapeutics (NASDAQ:JUNO) based on 8 analyst recommendation on the company stock is 1.38, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Juno Therapeutics (NASDAQ:JUNO) : Currently there are 8 street experts covering Juno Therapeutics (NASDAQ:JUNO) stock. The most bullish and bearish price target for the stock is $80 and $50 respectively for the short term. The average price target of all the analysts comes to $61.13. The estimated standard deviation from the target is $11.52.

For the current week, the company shares have a recommendation consensus of Buy. Also, Raymond James initiates coverage on Juno Therapeutics (NASDAQ:JUNO).The analysts at the brokerage house have a current rating of Outperform on the shares. The rating by the firm was issued on June 2, 2016.

Juno Therapeutics (NASDAQ:JUNO): stock turned positive on Tuesday. Though the stock opened at $38.54, the bulls momentum made the stock top out at $39.17 level for the day. The stock recorded a low of $38.11 and closed the trading day at $38.95, in the green by 4.06%. The total traded volume for the day was 1,371,307. The stock had closed at $37.43 in the previous days trading.

In an insider trading activity,The director of Juno Therapeutics, Inc., Klausner Richard sold 12,000 shares at $40.71 on June 24, 2016. The Insider selling transaction had a total value worth of $488,520. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *